1. Home
  2. NCMI vs SLDB Comparison

NCMI vs SLDB Comparison

Compare NCMI & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

HOLD

Current Price

$3.86

Market Cap

414.7M

ML Signal

HOLD

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

HOLD

Current Price

$5.64

Market Cap

444.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCMI
SLDB
Founded
2005
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
414.7M
444.9M
IPO Year
2007
2018

Fundamental Metrics

Financial Performance
Metric
NCMI
SLDB
Price
$3.86
$5.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
11
Target Price
$6.88
$14.82
AVG Volume (30 Days)
421.6K
910.7K
Earning Date
10-30-2025
11-03-2025
Dividend Yield
3.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$236,300,000.00
N/A
Revenue This Year
$3.66
N/A
Revenue Next Year
$12.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.81
$2.41
52 Week High
$7.25
$7.37

Technical Indicators

Market Signals
Indicator
NCMI
SLDB
Relative Strength Index (RSI) 36.38 51.25
Support Level $3.84 $5.68
Resistance Level $3.96 $6.08
Average True Range (ATR) 0.12 0.35
MACD -0.02 -0.02
Stochastic Oscillator 0.00 42.45

Price Performance

Historical Comparison
NCMI
SLDB

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Share on Social Networks: